AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02607800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOF/VEL
Description: 400/100 mg tablet administered orally once daily with or without food
Study NCT04372836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vasopressin injection
Description: The intervention consists of five steps: rupture the ovarian endometrial cyst and remove the ''chocolate fluid;'' inject diluted vasopressin solution into the interface between endometrioma and ovarian parenchyma; stop injecting until the solution overflow; separate the endometrioma away from the ovarian parenchyma; and coagulate bleeding spots and suture the ovary.
Study NCT02311205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Transarterial Chemoembolization (TACE)
Description: On demand conventional TACE will be performed in all the patients after enrollment and can be continued until intrahepatic CR, TACE failure or consent withdrawal. Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
Study NCT02311205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
Study NCT02445313 — intervention group
Intervention type: DEVICE
Intervention: Nidek MP-3
Description: Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD
Study NCT02855307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60-minute exercise
Description: Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.
Study NCT02855307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: Patient's insulin pump will be used to infuse insulin.
Study NCT02553239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolLoop®
Description: Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
Study NCT01107535 — intervention group
Intervention type: BIOLOGICAL
Intervention: Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.
Description: Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
Study NCT04576767 — intervention group
Intervention type: OTHER
Intervention: anaesthetic
Description: different states of consciousness
Study NCT00135395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir+ritonavir
Description: Capsules, Oral, 300mg/100mg, once daily, 24 weeks.
Study NCT02713360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Study NCT03485807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Description: 2 week SmartPhone-based mindfulness training
Study NCT03485807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Coping Training (CT)
Description: 2 week SmartPhone-based structurally equivalent coping training
Study NCT02855307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum glucose sensor
Description: The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
Study NCT00135395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir+ritonavir
Description: Capsules, Oral, 800mg/200mg, twice daily, 24 weeks.
Study NCT02353000 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases
Study NCT02353000 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Whole Brain Radiotherapy
Description: Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
Study NCT04380220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples and processing
Description: DSC perfusion technique at 3.0-T MRI only in MS patients
Study NCT05403021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GETCare Intervention
Description: This 5-week intervention was administered remotely and individually to caregivers utilizing phone, email, and a secure online platform. The GETCare program was mostly self-led and included five weekly module education topics: basics of stroke, caregiver skills, caregiver changes, meaningful participation, and community resources. Each module incorporated (1) individualized education, (2) goal setting, (3) skills training, and (4) community resource recommendations. The program was led by a licensed occupational therapist who is a certified stroke rehabilitation specialist. The occupational therapist conducted weekly check-ins via email or phone focused on answering questions, tracking goal progress, and assisting in problem solving.
Study NCT03356587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
Study NCT03246932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led psycho-education group
Description: A structured, researcher-designed peer-led psycho-education program (6 months), comprising of 12 bi-weekly, 2-hour group sessions.
Study NCT03991650 — intervention group
Intervention type: BEHAVIORAL
Intervention: Monitoring with a device
Description: Participants will be monitored by an App.
Study NCT03363776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986277
Description: Specified dose on specified days
Study NCT03363776 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT01564108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Series of intravitreal injections of Ranibizumab
Study NCT03246932 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Profession-led psycho-education group
Description: A psychoeducation group program (12 sessions, bi-weekly).
Study NCT03246932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine psychiatric care
Description: Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
Study NCT03246932 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine psychiatric care
Description: Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
Study NCT03246932 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine psychiatric care
Description: Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
Study NCT00870909 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: Intensity 2 mA during 20 minutes, 2 times per day
Study NCT00870909 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham tDCS
Description: sham condition as delivered by the stimulator
Study NCT01185288 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab in pre-filled syringes
Study NCT02855307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Patient's usual fast-acting insulin analog will be used.
Study NCT01185288 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab in pre-filled syringes
Study NCT01652768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Research Questionnaires
Description: Hospital Anxiety and Depression Scale Pearlin \& Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey
Study NCT01652768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research Questionnaires
Description: Hospital Anxiety and Depression Scale Pearlin \& Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey
Study NCT01185288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate capsule
Study NCT01185288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate capsule
Study NCT03317236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: A fixed 50 mg exteded release formulation.
Study NCT04203407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP game
Description: Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.
Study NCT04203407 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants in the control group will receive a 1-hour board game about health lifestyle.
Study NCT05164549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Injectable Product
Description: Investigational Medicinal Product
Study NCT02855307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-hormone closed-loop strategy
Description: Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
Study NCT05164549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Standard of Care
Study NCT05164549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Standard of Care
Study NCT01492062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiple Model Predictive Controller
Description: Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
Study NCT01768728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic left hemihepatectomy
Description: participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments
Study NCT01768728 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open left hemihepatectomy
Description: participants will be performed with traditional open left hepatectomy using laparotomic instruments
Study NCT04309409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg nivolumab fixed dose given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year
Study NCT03345316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFI-1010
Description: Intravenous single dosing
Study NCT00278512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant
Description: Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning
Study NCT00278512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplant
Description: Allogeneic Stem Cell Transplant will be performed after conditioning
Study NCT00278512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Causes prevention of the cell division
Study NCT00278512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG (rabbit)
Description: A rabbit polyclonal antibody to lymphocyte
Study NCT00278512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Hematopoietic growth factor
Study NCT00278512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1h
Description: Humanized monoclonal antibody against CD52 antigen
Study NCT00278512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: inhibits DNA synthesis or repair
Study NCT00278512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: immune suppressive drug
Study NCT00278512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs
Study NCT01652768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palliative Care Team
Description: Week 1: Early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse).~1. Introduce the palliative care team concept.~2. Provide contact information for the palliative care team given~3. Administer Initial Patient and Caregiver Psychosocial Assessments (Appendix A)~4. Offer community resources to patient and caregiver (Appendix B)~5. Provide additional resources/referrals for any needs that are identified by patient or care partner during initial psychosocial assessment~6. Provide supportive care
Study NCT01652768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Information Session for Patients and Caregivers
Description: Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver Week 5 through 7: The PRESENCE Project Social Worker and oncology RN will provide an educational class.~Intervention (Length of time for class = 2 hours):~1. Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver.~2. Provide additional resources/referrals for any needs that are identified by patient or care partner during the educational class.~3. Provide supportive care.
Study NCT01652768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contact every 2 weeks
Description: The PRESENCE Project APN and/or Presence Project Social Worker will contact the patient and caregiver via telephone or office visit every two weeks and as needed until the second medical oncology visit.~(Anticipated length of time for phone intervention or visit is 20 minutes; however, length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Provide pain and/or symptom management intervention for any issues identified during the follow-up assessment~3. Provide resources/referrals for any needs identified during the social work follow-up assessment~4. Provide supportive care
Study NCT01652768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up Surgical Visit Session
Description: The PRESENCE Project APN will meet with patient and caregiver at the surgical follow-up visit, approximately two weeks after surgery.~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Administer Symptom Assessment Tool~3. Provide pain and/or symptom management intervention~4. Provide supportive care
Study NCT01652768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical and/or Radiation Oncology Appointment Session
Description: The PRESENCE Project APN and/or Presence Project Social Worker will meet with patient and caregiver at the first medical and/or radiation oncology appointment (weeks 3 and 4).~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~1. Administer Patient and Caregiver Follow-up Assessment~2. Re-assess pain and/or symptom management issues and /or intervention~3. Provide resources/referrals for any needs identified during the social work follow-up assessment~4. Provide supportive care.
Study NCT00597636 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionaire, blood sample
Description: Provide 30ml blood for laboratory assays Complete Health Questionnaire
Study NCT00597636 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionaire, Blood sample
Description: Provide 30ml blood for laboratory assays Complete Health Questionnaire
Study NCT03570411 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T-SPOT®.CMV Test
Description: The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens. Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified. The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study. Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines. We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC. Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout. That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).
Study NCT01291498 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High Intensity Focused Ultrasound
Description: One or two HIFU sessions
Study NCT03300791 — intervention group
Intervention type: OTHER
Intervention: Admitted
Description: Readmitted patients in the next months after an episode of aute heart failure will be recruited. Controls will be selected between those who were admitted in the baseline but not readmitted in this month.
Study NCT01787448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical gel vehicle
Description: 0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
Study NCT01787448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium lauryl sulfate 0.1%
Description: 0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
Study NCT01787448 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium chloride solution 0.9% (saline)
Description: 0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
Study NCT01738750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cost Information Included
Study NCT03469128 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive processing therapy
Description: Psychological treatment for patients suffering from PTSD and SUD symptoms.
Study NCT03469128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline for the treatment of post-traumatic stress and SU disorders
Study NCT03469128 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo Control
Study NCT00324025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycograb
Study NCT00324025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT01568034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 25 mg single-dose
Study NCT04285450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: 1mg
Study NCT01568034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 50 mg single-dose
Study NCT01568034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 100 mg single-dose
Study NCT04285450 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose
Study NCT04434807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive hematoma evacuation
Description: Neurosurgery performed via burr hole or minicraniotomy and using the Aurora surgiscope and evacuator (Integra Lifesciences)
Study NCT02116348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Nerve growth factor)
Description: Cerebrolysin will be given to the intervention group
Study NCT04497792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10Mg Tab
Description: Patients from treatment group received empagliflozin 10 mg daily additionally to previously prescribed diabetes medication
Study NCT04497792 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: hypoglycemic therapy
Description: hypoglycemic therapy.
Study NCT03351855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-CTLs
Description: 2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg by IV each time
Study NCT04769726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: almonds
Description: almond intervention (20 g) before three major meals (60g per day) for 3 days in subacute phase, before OGTT in the acute phase ad for 3 months in chronic phase